Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAX-DN: Esaxerenone vs Placebo in Japanese Type 2 Diabetic Patients with Microalbuminuria
jRCT2080223639Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis, hypertension (HTN) and 1 more comparing Esaxerenone once daily with Placebo once daily (2 arms). Primary endpoints: UACR remission rate and UACR reduction. Started Sep 2017; status: completed.
02
Drugs
esaxerenone
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosishypertension (HTN)Microalbuminuria
Beyond the preview
Go deeper on jRCT2080223639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223639.